在体重管理中,阿卡尔对奥利斯塔特的辅助效果 - - 一个随机,双盲,多臂的第二阶段试验
Ulf Holmbäck1, Stefan Grudén2, Sandra Kuusk3
1Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden.
Obesity (Silver Spring, Md.)
|August 6, 2025
概括
与单独的orlistat相比,Acarbose与EMP16中的orlistat结合使用显著增加了体重减轻. 这种组合疗法对有效的肥胖管理具有前景.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
- 临床试验 临床试验
背景情况:
- 肥胖是一种复杂的代谢疾病,需要有效的长期管理策略.
- 奥尔利斯塔特是一种成熟的抗肥胖药物,但它的疗效可以提高.
- 甲糖,主要是一种抗糖尿病药物,在体重管理方面表现出潜力.
研究的目的:
- 为了评估阿卡尔对奥利斯塔特减肥功效的协同效应.
- 评估一种新型组合药物EMP16在肥胖患者的疗效.
- 为了比较EMP16与改性释放和常规orlistat的减肥结果.
主要方法:
- 一个为期6个月的双盲随机试验,涉及240名肥胖或超重的参与者.
- 研究了三个组:EMP16 (orlistat/acarbose),改变释放的orlistat (MR-O) 和常规的orlistat (Conv-O).这些组的研究结果是:
- 主要结局包括6个月后的相对和分类体重减轻.
主要成果:
- EMP16实现了7.73%的平均相对减重,明显高于MR-O (-5.78%) 和Conv-O (-5.13%).
- 在EMP16组中,更高比例的参与者实现了≥5%和≥10%的体重减轻.
- 与Conv-O相比,EMP16在脂肪肝指数和生活质量方面表现得更好,没有严重的不良事件.
结论:
- 在EMP16配方中,阿卡波斯显著增强了orlistat的减肥效果.
- EMP16代表了长期肥胖管理的安全和有效的治疗选择.
- 综合疗法需要进一步研究其在改善代谢健康中的作用.
相关概念视频
01:11Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...